Provided herein are methods, compounds, and compositions for reducing expression of ApoCIII mRNA and protein in a patient with Partial Lipodystrophy. Also provided herein are methods, compounds, and compositions for treating, preventing, delaying, or ameliorating Partial Lipodystrophy in a patient. Further provided herein are methods, compounds, and compositions useful to treat, prevent, delay, or ameliorate any one or more of pancreatitis, cardiovascular disease or metabolic disorder, or a symptom thereof, associated with Partial Lipodystrophy in a patient.
